Living the Japanese bioventure (Pepti)dream
This article was originally published in Scrip
You may also be interested in...
Emerging Company Profile: Using IP licensed from Yale, Kleo is betting it can complement or replace existing immuno-oncology drugs, specifically Darzalex. In partnership with PeptiDream, it just unveiled its first candidate for clinical development.
Merck & Co is tapping government scientific researchers in Singapore to help overcome some of the limitations of macrocyclic peptide therapeutics.
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.